Two meaningful successes in this field include the approval of Trastuzumab (Herceptin; Genentech) in 1988 for treating HER2-positive metastatic breast cancer patients, and Imatinib (Gleevec; Novartis) in the early 2000s to treat chronic myeloid leukemia (CML) by targeting BCR-ABL tyrosine kinase (Jorgensen, 2019). This evidence concerns the gene ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive.